Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T M Habermann

Showing results (31-40 of 95) with videos related to

Pageof 10
Sort By:
American Journal of Clinical Pathology|September 1, 1985
Evaluation of the Coulter Counter model S-Plus IVC J Cox, T M Habermann, B A Payne, et al.
The Journal of Experimental Medicine|September 1, 1983
Localization of eosinophil granule major basic protein in human basophilsS J Ackerman, G M Kephart, T M Habermann, et al.
American Journal of Clinical Oncology|June 17, 2000
Phase II trail of didemnin B in previously treated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group (ECOG) StudyO Kucuk, M L Young, T M Habermann, et al.
Leukemia & Lymphoma|March 26, 2002
Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosisS Kanelli, S M Ansell, T M Habermann, et al.
Mayo Clinic Proceedings|April 1, 1994
Incidence of leukemia in Olmsted County, Minnesota, 1975 through 1989T G Call, P Noël, T M Habermann, et al.
Clinical Lymphoma|November 15, 2001
A randomized, placebo-controlled study of outpatient premedication for bone marrow biopsy in adults with lymphomaA P Wolanskyj, G Schroeder, P R Wilson, et al.
Cancer|September 15, 1995
S-phase fraction by the labeling index as a predictive factor for progression and survival in low grade non-Hodgkin's lymphomaT E Witzig, T M Habermann, P J Kurtin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOML I Gordon, J Anderson, T M Habermann, et al.
Leukemia & Lymphoma|March 26, 2002
Efficacy of splenectomy for patients with mantle cell non-Hodgkin's lymphomaY Yoong, P J Kurtin, C Allmer, et al.
The Laryngoscope|February 1, 1996
Nasal and nasopharyngeal angiocentric T-cell lymphomasS P Davison, T M Habermann, J G Strickler, et al.
Pageof 10

Showing results (31-40 of 95) with videos related to

Sort By:
Pageof 10
American Journal of Clinical Pathology|September 1, 1985
Evaluation of the Coulter Counter model S-Plus IVC J Cox, T M Habermann, B A Payne, et al.
The Journal of Experimental Medicine|September 1, 1983
Localization of eosinophil granule major basic protein in human basophilsS J Ackerman, G M Kephart, T M Habermann, et al.
American Journal of Clinical Oncology|June 17, 2000
Phase II trail of didemnin B in previously treated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group (ECOG) StudyO Kucuk, M L Young, T M Habermann, et al.
Leukemia & Lymphoma|March 26, 2002
Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosisS Kanelli, S M Ansell, T M Habermann, et al.
Mayo Clinic Proceedings|April 1, 1994
Incidence of leukemia in Olmsted County, Minnesota, 1975 through 1989T G Call, P Noël, T M Habermann, et al.
Clinical Lymphoma|November 15, 2001
A randomized, placebo-controlled study of outpatient premedication for bone marrow biopsy in adults with lymphomaA P Wolanskyj, G Schroeder, P R Wilson, et al.
Cancer|September 15, 1995
S-phase fraction by the labeling index as a predictive factor for progression and survival in low grade non-Hodgkin's lymphomaT E Witzig, T M Habermann, P J Kurtin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOML I Gordon, J Anderson, T M Habermann, et al.
Leukemia & Lymphoma|March 26, 2002
Efficacy of splenectomy for patients with mantle cell non-Hodgkin's lymphomaY Yoong, P J Kurtin, C Allmer, et al.
The Laryngoscope|February 1, 1996
Nasal and nasopharyngeal angiocentric T-cell lymphomasS P Davison, T M Habermann, J G Strickler, et al.
Pageof 10